VANCOUVER, BC / ACCESSWIRE / May 28, 2020 / YDX Innovation Corp. (TSX-V:YDX) (OTC PINK: YDRMF) (FSE:A2PB03) ("YDX" or the "Company"), is pleased to announce that it has entered into a definitive arm's length share purchase agreement dated May 27th, 2020 (the "Agreement") with Purple Mage Advisors Ltd. ("PMA") and the shareholders of PMA (collectively, the "Vendors"), pursuant to which YDX has agreed to acquire all of the issued and outstanding shares PMA from the Vendors (the "Transaction").

About the acquisition, Daniel Japiassu, CEO of YDX Innovation stated: "We continue to be very excited about our esports initiatives and are looking forward to having the PMA team on board. Data mining and analysis are key sectors to be explored that connect different aspects of what we do. As YDX explore bringing more companies to our group, we anticipate having their expertise in the future to gather, interpret and use data in our advantage and as a possible new revenue stream and support to other divisions, like Arkave Studios and Beat Gaming."

About Purple Mage Advisors

PMA is a research and data analysis firm that specializes in player recruitment and development within the gaming industry. PMA helps esports and gaming companies with industry reports, player recruitment, player training, data analysis and relevant statistical reporting. PMA uses regression analysis methods to sort through large amounts of information to find statistically significant data points.

The Company is interested in the use of these data points to formulate reports that help organizations succeed in the gaming industry. PMA's experts in industry research can help find the best esports players and develop the appropriate training programs needed to construct a successful esports team.

"The PMA team is excited about this opportunity to join forces with YDX and its group of companies," says Arnoldas Dogelis, President of PMA. "We look forward to providing additional insights into YDX's internal operations and endeavors, while refining our applications and growing our collective businesses."

Transaction Terms

The terms of the Agreement include payment of consideration by YDX to the Vendors in the amount of $440,000, which amount is payable by the issuance of 4,000,000 shares in the capital of YDX on closing of the Transaction at a deemed price of $0.11 per share. Closing of the Transaction is subject to a number of conditions common to similar share purchase transactions, including YDX's completion of a satisfactory due diligence review of PMA and approval from the TSX Venture Exchange (the "TSXV").

The Company anticipates that the Transaction will constitute an Expedited Transaction in accordance with the policies of the TSXV.

Japiassu further comments that: "Our believe that it's possible to accelerate the growth of the YDX Group by strategic acquisitions, such as Beat Gaming and Purple Mage Advisors. This way, we can bring new areas of expertise to the company, increase the potential for internal collaboration and diversify of our revenues streams. Esports is a rapidly growing industry and, as such, timely opportunities for investment might appear; we see data mining as one of these. A growing number of young players start to compete in different games and will need to measure and improve their gaming skills. As esports can leads to different career opportunities and university scholarships, analytics might play an important role. We anticipate that the potential of the acquisition of this young company, with incredible potential, could be an opportunity to expand our resources to further develop our position in the immersive experiences market."

About YDX Innovation

YDX Innovation Corp. (TSXV- YDX :: www.ydxinnovation.com) is a technology company that develops products and services and is an expert in immersive technologies like Augmented and Virtual Reality, eSports events and Interactive Exhibitions under the following three divisions:

Arkave VR Arena – https://sales.arkavevr.com/ – a gaming platform that brings the most immersive Virtual Reality experience to Location-Based venues with a highly scalable business model. Developed as an all-in-one gamers haven featuring state-of-the-art free room tech right down to the most nostalgic gaming systems.

YDreams Global – www.ydreamsglobal.com – have developed over 1,300 interactive experiences for clients all over the world such as Disney, NBA, Adidas, Cisco, Nokia, Nike, Mercedes-Benz, Coca-Cola, Santander, AmBev, Qualcomm, Unilever, City of Rio and Fiat.

BEAT Gaming – www.beat.gl -Founded in 2011, BEAT Gaming is an experienced Canadian esports company that has organized internationally recognized events such as the Dota 2, Overwatch and PUBG BEAT Invitational. Since its creation, BEAT has organized over 30 professional and semi-pro esports events, which have reached over 40 million views globally.

Game On Festival – www.gameonfestival.com – is an interactive entertainment event that celebrates the video game universe. Designed for gamers, families and fans of all ages, this Festival is a fusion of culture, entertainment and fun through Interactive Exhibits, Game Arenas, eSports Tournaments, high impact collective experiences, among other fun activities, all brought together in one large exhibition-style event.

More Information:

Daniel Japiassu
Director and CEO
dj@ydx.rocks
(604) 704-6466

contact@ydxinnovation.com | www.ydxinnovation.com | www.youtube.com/ydreamsglobal

This news release may contain "forward-looking statements" within the meaning of applicable Canadian securities laws, including, without limitation: the closing of the Transaction; and the Company obtaining all consents and TSXV approvals in order to close. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies. These statements generally can be identified by the use of forward-looking words such as "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause future results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. The Company's statements expressed or implied by these forward-looking statements are subject to a number of risks, uncertainties, and conditions, many of which are outside of the Company's control, and undue reliance should not be placed on such statements. Forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding the Transaction, including: that the Company's assumptions in making forward-looking statements may prove to be incorrect; adverse market conditions; the inability of YDX to complete the Transaction on the terms announced or at all; the inability of YDX to finance any necessary costs associated with the Transaction; risks relating to the satisfaction of the conditions to closing the Transaction; that future results may vary from historical results; and that market conditions or competition may affect the outcome of the Transaction and the business. Except as required by securities law, the Company does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: YDX Innovation Corp.

ReleaseID: 591798

Speedy approval of new diabetic neuropathy drugs by regulatory bodies such as Food and Drug Administration (FDA) will augur well for market growth.

ROCKVILLE, MD / ACCESSWIRE / May 28 2020 / Accelerating R&D activities by top pharmaceutical companies in creating anti-diabetic formulations aimed at treating 1/10th of global population will bode well for market. According to Fact.MR's analysts, the global diabetic neuropathy market will exhibit brisk growth at approximately 5.6% CAGR over the duration of projection period (2020-2025). Moreover, the supplies of insulin and novel drugs have not been severely affected by the COVID-19 pandemic. Leaders in diabetic neuropathy market are exploring the whitespaces such as underdiagnoses of neuropathic patients.

"Prominent companies must divert funding towards drug development through escalated R&D undertakings," finds Fact.MR

Request PDF Sample of the 170-page report on the Diabetic Neuropathy Market-

https://www.factmr.com/connectus/sample?flag=S&rep_id=4698

Key Takeaways of Diabetic Neuropathy Market Study

Use of proximal neuropathy in treating type 2 diabetes patients will gain traction during the projection period.
Drugs are the most preferred type of treatment among healthcare professionals in diabetic neuropathy market.
Peripheral neuropathy segment will capture about 50% share in the overall market stack.
North America diabetic neuropathy market continues to generate about 2/5th of total demand.

Diabetic Neuropathy Market – Key Drivers

Increasing product pipeline by established diabetic neuropathy drug manufacturers is fuelling the market growth.
A large population pool of diabetic patients in developing nations such as India will propel the growth of diabetic neuropathy market during the forecast period.
Limited healthcare infrastructure and poor dietary habits will drive demand in emerging Asian economies through 2025.
Higher percentage of diagnosed patients and development of new therapies and drugs in North America will complement the growth of the regional market.

Diabetic Neuropathy Market – Key Impediments

Processing of orders may be delayed in view of remote workforce and imminent threat of their safety amid COVID-19.
Underdiagnoses of patients and limited treatment options in developing countries will restrain market growth over the forecast period.

Explore 90 tables and 67 figures of the study. Request ToC of the report at-

https://www.factmr.com/report/4698/diabetic-neuropathy-market

Anticipated Impact of COVID-19 on Diabetic Neuropathy Market

One of the most vulnerable population groups during the ongoing COVID-19 pandemic are diabetic patients. According to World Health Organization (WHO), the average mortality rate from COVID-19 is the highest among diabetic patients, followed by hypertension patients. Hence, the significance of diabetic neuropathy has multiplied in the past three months. Diabetic patients have higher chances of inflammation and internal swelling due to COVID-19. Further, top producers of diabetic neuropathy market have reported minimal effects of the pandemic on their distribution and manufacturing capabilities. There will be no shortage of diabetic neuropathy drugs according to industry experts. Hence, the overall prospects of diabetic neuropathy market are positive both in terms of sales and supply chain management.

Competition Landscape of Diabetic Neuropathy Market

The global diabetic neuropathy market is characterized by a highly consolidated competitive landscape. Some of the prominent companies in the global diabetic neuropathy market that are profiled in this Fact.MR report include, but are not limited to, Depomed, Inc., Arbor Pharmaceuticals, LLC, Glenmark Pharmaceuticals Ltd., Pfizer, Inc., Astellas Pharma Inc., Lupin Limited, Eli Lilly and Company, NeuroMetrix, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson (Janssen Global Services, LLC), Merck KGaA, and GlaxoSmithKline Plc. Key stakeholders in diabetic neuropathy market are concentrating their efforts on new drug development. For instance, Janssen Global Services, LLC produces several diabetic neuropathy drugs including INVOKANA, Duragesic, and NUCYNTA ER.

About the Report

This 170-page study offers in-depth commentary on the diabetic neuropathy market. The study provides compelling insights on the diabetic neuropathy market on the basis of disorder type (autonomic neuropathy, proximal neuropathy, peripheral neuropathy, and focal neuropathy), treatment type (physiotherapy, radiotherapy, and drugs), and distribution channel (online pharmacy, retail pharmacy, clinics, and hospitals) across five key regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

Explore Fact.MR's Comprehensive Coverage on Healthcare Landscape

Hospital Asset Management Market – Get Fact.MR's detailed coverage on the global hospital asset management market covering supply chain analysis, value chain analysis, prominent companies, vital dynamics, and performance statistics for predefined projection period (2020-2026).

Orthopedic Devices Market – Fact.MR's latest study on the global orthopedic devices market encompasses accurate qualitative and quantitative insights for the course of forecast period (2020-2026).

Animal Parasiticides Market – Find out about major growth-oriented strategies of key players, investment opportunities, historical growth analysis and forecast for the global animal parasiticides market through Fact.MR's report during 2020-2026.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at Fact.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over thousand reports and 1 million+ data points, the team has scrutinized the Healthcare sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latest market reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1445/global-diabetic-neuropathy-market

SOURCE: Fact.MR

ReleaseID: 591789

Sustainable attributes of emollient esters will drive its adoption in personal care products in near future.

ROCKVILLE, MD / ACCESSWIRE / May 28, 2020 / Role and suitability of emollients in cosmetic applications is the major growth engine of the emollients market. Emollients in a variety of forms such as fatty alcohols, silicones, hydrocarbons, ethers, esters, and fatty acids are in great demand. According to Fact.MR's analysts, the global emollient market will exhibit promising growth, with semi-solid emollients segment generating 1/3rd of total demand. Moreover, favorable attributes such as excellent spreadability and solubility of emollients will tip the scale in favor of the market during the course of projection period (2020-2030).

"Business leaders must contemplate strategies such as product innovation and acquisitions to sustain in the post-pandemic future," concludes Fact.MR.

Request PDF Sample of the 170-page report on the Emollient Market-

https://www.factmr.com/connectus/sample?flag=S&rep_id=1731

Key Takeaways of Emollient Market Study

Use of emollients in fatty alcohol and fatty acids is gaining traction owing to prolific demand for lotions and creams.
Skin hydrates segment will generate approximately 60% of total demand for emollients during the forecast period.
The emollient market in Asia Pacific Excluding Japan (APEJ) will expand 2X through 2030.
North American emollient market will offer remunerative opportunities for established regional manufacturers

Emollient Market – Key Drivers

Soaring demand for skincare and hair care products will inflate sales of emollients over the forecast period.
Expanding geriatric population pool is augmenting the demand for personal care products and thereby emollient esters.
Growing adoption of cosmetic products by the younger generation continues to fuel the demand for emollients.
Proliferation of bio-based beauty and personal care products will contribute substantially to the revenue pools of the emollient market.
The availability of raw materials and presence of key manufacturers will favor market growth in APEJ through 2030.

Emollient Market – Key Impediments

Relatively high price point of emollients will restrain the growth of market during the projection period. Hence, manufacturers must work on competitive pricing strategy to mitigate this factor.
Certain side-effects such as skin irritation associated with the usage of emollients in cosmetic products will hamper the market growth through 2030.

Explore 108 tables and 94 figures of the study. Request ToC of the report at-

https://www.factmr.com/report/1731/emollient-market

Anticipated Impact of COVID-19 on Emollient Market

Most nations remain sceptical about the possibility of COVID-19 coming to an end anytime soon. Leading companies in the emollient market have realized that they must operate alongside the COVID-19 pandemic for the latter half of 2020. Innovation in product designs and marketing strategies will decide the fate of prominent players in emollient market. Companies must venture into protective personal care rather than restrict themselves to cosmetics. In the wake of ongoing pandemic, the demand for hygiene-focused products such as hand sanitizers, soaps, and wet wipes has amplified. On the other hand, sales of moisturizers, hand creams have slightly dipped. Hence, this trend will persist through the duration of pandemic.

Competition Landscape of Emollient Market

Some of the prominent companies in the emollient market that are featured in this Fact.MR report include, but are not limited to, Dow Chemical Co., CLARIANT AG, BASF SE, EASTMAN CHEMICAL COMPANY, Croda International PLC, EVONIK INDUSTRIES AG, LONZA GROUP, Stepan Company, LUBRIZOL CORPORATION, and SOLVAY. Major manufacturers are planning massive investments in product launch activities. For instance, STEPAN introduced natural ingredient-based STEPAN-MILD in 2019. On the other hand, BASF SE launched Inolixir, Hydrasensyl, and Hydagen in January 2020. These products boast of various active ingredients which combine skincare benefits with makeup needs of consumers.

About the Report

This 170-page study offers in-depth commentary on the emollient market. The study provides compelling insights on the emollient market on the basis of form (solid, semi-solid, liquid, and power/flakes), chemical type (ester, fatty alcohols, fatty acids, ether, silicones, and hydrocarbons), and application (skin care, hair care, oral care, fragrances, toiletries, and cosmetics) across six key regions (North America, Latin America, Europe, Japan, Asia Pacific Excluding Japan, and Middle East & Africa).

Explore Fact.MR's Comprehensive Coverage on Retail & Consumer Goods Landscape

Functional Workwear Apparel Market – Get Fact.MR's in-depth analysis on the global functional workwear apparel market covering winning strategies, revenue shares, and product portfolio analysis of leading players for predefined projection period (2020-2030).

Collapsible Crates Market – Find out about vital dynamics, growth projection, performance parameters, and historical growth analysis of the global collapsible crates market through Fact.MR's study for the course of forecast period (2020-2030).

Massage Oil Market – Fact.MR's deep-dive insights on the global massage oil market covers segmental analysis, region-wise data, and competitive landscape for 2020-2030.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at Fact.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over thousand reports and 1 million+ data points, the team has scrutinized the Retail & Consumer Goods sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latest retail industry market reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1454/global-emollient-market

SOURCE: FactMR

ReleaseID: 591782

CHARLOTTESVILLE, VA / ACCESSWIRE / May 28, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the appointment of Dr. Jack Reich to the Board of Directors. The appointment increases the Board to seven members. Dr. Reich will serve on the Audit Committee as well as the Nominations and Corporate Governance Committee.

Dr. Jack Reich's career spans over 35 years in the pharmaceutical, biotechnology, and venture capital industries. Since 1987, Dr. Reich has been involved in more than 30 medical and biotech companies. He was a founding officer of Gensia, Inc. and co-founded the first gene therapy company, Viagene, Inc. Following its public listing, Gensia soon became the second-largest market cap biotech on NASDAQ, and Viagene was acquired by Chiron after its public listing. Dr. Reich also co-founded the first cardiovascular gene therapy company, Collateral Therapeutics, Inc., which he took public on NASDAQ in 1997 as Chairman and CEO. Subsequently, Collateral was sold to Schering AG in 2002. In 2009, Dr. Reich co-founded Renova Therapeutics, where he served as CEO until 2019.

William Stilley, President and Chief Executive Officer of Adial Pharmaceuticals, commented, "We are pleased to welcome Jack to the Board of Directors. His industry experience and successful track record, including oversight of the development of dozens of approved therapies, should be invaluable as we work to advance Adial's ONWARD™ Phase 3 pivotal trial of AD04 in genetically identified subjects for the treatment of Alcohol Use Disorder (AUD) and as we evaluate regulatory opportunities and strategic options in the field of addiction. The addition of an independent director of Jack's caliber also enhances our practice of maintaining strong corporate governance."

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ Phase 3 Pivotal Clinical Trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adialpharma.com.

Forward Looking Statements

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the expected contribution of Dr. Reich and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to expand the use of AD04 for use in patients with Opioid Use Disorder, gambling and obesity, the ability of AD04 therapy to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q and Current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:

Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com

SOURCE: Adial Pharmaceutical, Inc.

ReleaseID: 591783

BOSTON, MA / ACCESSWIRE / May 28, 2020 / Block & Leviton LLP alerts investors in Credit Acceptance Corporation (NASDAQ:CACC) that the firm is investigating possible securities laws violations involving the Company and certain of its executives. Investors who have lost money are encouraged to contact the firm for a free case evaluation.

On March 25, 2020, analyst Citron Research published a report in which Citron first highlighted the steep upward trend in subprime auto loan delinquencies. Citron then observed that CACC has been taking on increasingly risky and lower return loans, "hiding the true volatility of its earnings through aggressive accounting." Citron further called into question the accuracy of the reported book value of CACC's loans.

On April 20, 2020, after the markets closed, the Company disclosed that it would not timely file its quarterly report for the period ended March 31, 2020. In one day, the price of CACC shares fell $40.71 per share, or over 13%.

Then today, May 27, 2020, after the markets closed, CACC announced a consolidated net loss of $83.8 million, or $4.61 per diluted share, for the three months ended March 31, 2020 – compared to net income of $164.4 million, or $8.65 per diluted share, for the same quarter in 2019. These quarterly financial results also included "a provision for credit losses of $354.7 million."

CACC investors who have lost money are encouraged to contact Block & Leviton attorneys at (617) 398-5600, via email at cases@blockesq.com, or at https://shareholder.law/cases/?case=cacc.

Block & Leviton LLP (www.blockesq.com) is a nationwide firm dedicated to representing investors and maintaining the integrity of the country's financial markets. The firm represents many of the nation's largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm's lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockesq.com
SOURCE: Block & Leviton LLP

www.blockesq.com

SOURCE: Block & Leviton LLP

ReleaseID: 591792

TEMPE, AZ / ACCESSWIRE / May 28, 2020 / Wrap Technologies, Inc. (the "Company" or "Wrap") (NASDAQ:WRTC), an innovator of modern policing solutions, announced that Tom Smith, President of Wrap Technologies, is scheduled to be interviewed live this morning via Skype on Newsmax-TV Channel on the "National Report" program. Smith will be discussing the BolaWrap and pandemic policing during the era of COVID-19 and social distancing.

Details of the broadcast are as follows:

Date: Thursday, May 28, 2020
Scheduled Start Time: 11:30amEST*
Network: Newsmax-TV
Network Show: National Report
Hosts: Shaun Kraisman & Emma Rechenberg

The live broadcast can be viewed on cable television and online via this link.

To learn more about National Report on Newsmax-TV, please visit: https://www.newsmaxtv.com/Shows/National-Report.

*Start times are subject to change

About Wrap Technologies (Nasdaq: WRTC)

Wrap Technologies is an innovator of modern policing solutions. The Company's BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the Company's Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. For information on the Company please visit www.wraptechnologies.com. Examples of recent media coverage are available as links under the "Media" tab of the website.

Trademark Information: BolaWrap and Wrap are trademarks of Wrap Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

Cautionary Note on Forward-Looking Statements – Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company's overall business, total addressable market and expectations regarding future sales and expenses. Words such as "expect," "anticipate," "should," "believe," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "could," "intend," variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company's ability to successful implement training programs for the use of its products; the Company's ability to manufacture and produce product for its customers; the Company's ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company's product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company's ability to maintain and enhance its brand, as well as other risk factors included in the Company's most recent quarterly report on Form 10-Q and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

WRAP TECHNOLOGIES' CONTACT:

Paul M. Manley
VP – Investor Relations
612-834-1804
pmanley@wraptechnologies.com

SOURCE: Wrap Technologies, Inc.

ReleaseID: 591788

LONDON, UK / ACCESSWIRE / May 28, 2020 / The domino effect of COVID-19 has slowly broken-down crucial parts of our lives. The economy has taken a huge detour, global fatality rates are climbing and social distancing has changed the way we live. The pandemic has also however spurred a great deal of compassion, healthcare innovation and philanthropy. Family offices all over the UK are launching initiatives to flatten the curve and join the battle against the Coronavirus.

Brady Wealth Management for flattening the curve

Given the existing lock down measures in the UK amid 265 thousand confirmed cases and over 37 thousand deaths, philanthropy is no easy feat. Partners at Brady Wealth Management have launched initiatives to help communities even in the midst of a lock down while respecting WHO social distancing guidelines.

Managing Partner, James Hambury, is using the firm's high-end concierge services to help communities that are on heavy lockdown with effective supply distribution to those in need. Masks, gloves and cleaning supplies are to be donated to more vulnerable communities during the epidemic with curbside drop-offs and text notifications.

Another community in desperate need comprises the dedicated healthcare workers and care providers. Shortages of hospital gowns, masks or any on-demand hospital equipment is part of the care package offered by Brady Wealth Management.

"I found that family offices are uniquely positioned to promote social solidarity during this crisis – with the financial backing to create a positive impact for local communities, and an impactful example of families more than willing to step up and leave a positive legacy behind", says manging partner James Hambury.

Families under the firm's management agree that some communities simply cannot afford to stay home, so they're making it easier for them to access essentials they would need to leave home to acquire.

Setting the standards for philanthropy in the age of Corona

Family offices are more than ever in a position to greatly support global economies and communities. Impact investment projects are a major trend in the industry as over 17% of the world's $50 billion under management goes to impact investment. Influential families are now uniting behind combatting corona much like many of the big initiatives led by conglomerates like Mastercard's COVID-19 Therapeutics Accelerator or the Wellcome Trust initiative by the Bill and Melinda Gates foundation.

On the UK front, other more community-oriented volunteers are rising to the occasion by organising mutual aid groups to support vulnerable people during the outbreak. Covid Mutual Aid UK focuses on bridging the gap between vulnerable local groups and volunteers. The Duke of Cambridge has also been contributing through the National Emergencies Trust (NET) to unite charities and major UK bodies with an aim to raise and distribute funds for victims of such natural and extraordinary circumstances.

The key to surviving pandemics is in the way people, governments and even family offices band together to protect vulnerable communities and support our social structure.

Media Contact:

Company: Brady Wealth Management
Contact person: James Hambury
Website: http://www.bradywealthmgmt.com
Email: contact@bradywealthmgmt.com

SOURCE: Brady Wealth Management

ReleaseID: 591786